Wugen

Based in St. Louis, Missouri, this clinical stage immuno-oncology cell therapy company is focused on the development of off-the-shelf NK and CAR-T cell therapies. These therapies are aimed at treating both solid tumor and heme malignancies. The company utilizes MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support their programs for hematologic and solid tumor cancers.